Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.39 |
| ▸ | GOT1 | P17174 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 2/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 5/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.37 |
| ▸ | AKT1 | P31749 | 2/20 | 0.37 |
| ▸ | AKT2 | P31751 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | TYK2 | P29597 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15052837 | 0.92 | AURKA (0.42) | BTKMAP3K7BRAFAURKAAURKB | |
| SCHEMBL15052980 | 0.92 | BRAF (0.46) | BTKALDH1A1MAP3K7GOT1BRAF | |
| SCHEMBL15053103 | 0.92 | MAP3K7 (0.39) | BTKMAP3K7GOT1BRAFSTING1 | |
| SCHEMBL15053470 | 0.92 | BTK (0.40) | BTKHTTRAB9AMAP3K7BRAF | |
| SCHEMBL15053064 | 0.92 | MAP3K7 (0.41) | BTKNPC1RAB9ASMN1; SMN2MAP3K7 | |
| SCHEMBL3709377 | 0.92 | MAPT (0.41) | BTKMAPTNPC1ALDH1A1LMNA | |
| SCHEMBL15052843 | 0.90 | BRAF (0.45) | MAPTHTTRAB9AMAP3K7GOT1 | |
| SCHEMBL15052603 | 0.90 | BRAF (0.44) | BTKNPC1HTTRAB9ASMN1; SMN2 | |
| SCHEMBL15054097 | 0.90 | BRAF (0.38) | BTKMAP3K7GOT1BRAFAKT1 | |
| SCHEMBL15053275 | 0.90 | MAP3K7 (0.44) | BTKMAPTNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165475-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ASCEPION PHARMACEUTICALS, INC. (CN) | 2013-06-27 | — | — | US | claimed |
| US-20130165475-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ASCEPION PHARMACEUTICALS, INC. (CN) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165475-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK2, CDK1, CDK3 | BTK 337/4885MAPT 1276/4885NPC1 3123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.